For neurosurgeons, radiation oncologists, hospital administrators, and medical technology investors, the treatment of small-to-medium brain lesions—brain metastases, arteriovenous malformations (AVMs), meningiomas, vestibular schwannomas, pituitary adenomas, and functional disorders such as trigeminal neuralgia—has been revolutionized by Gamma Knife Radiosurgery (GKRS). Traditional open brain surgery for deep-seated or eloquent-area lesions carries prohibitive risks: neurological deficit, infection, bleeding, lengthy recovery (weeks to months), and inoperability for multiple or recurrent metastases. Conventional fractionated radiotherapy (30+ sessions) delivers lower dose per fraction, requiring more treatments, increasing patient inconvenience, and exposing larger brain volumes to radiation. Gamma Knife Radiosurgery (GKRS)—a form of stereotactic radiosurgery delivering many highly focused gamma-ray beams from cobalt-60 (⁶⁰Co) sources converging on a defined intracranial target—creates a high ablative dose at the target while limiting dose to surrounding brain. With extreme geometric precision, sharp dose fall-off, and non-invasive workflows, GKRS preserves surrounding eloquent brain structures while achieving strong local control. This industry deep-dive analysis, based on the latest report by Global Leading Market Research Publisher QYResearch, integrates Q4 2025–Q2 2026 market data, real-world clinical deployment case studies, and exclusive insights on head Gamma Knife vs. body Gamma Knife applications and linac-based SRS competition. It delivers a strategic roadmap for healthcare executives and investors targeting the expanding US$297 million Gamma Knife market.
Market Size and Growth Trajectory (QYResearch Data)
According to the just-released report *“Gamma Knife Radiosurgery (GKRS) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*, the global market for Gamma Knife Radiosurgery was valued at approximately US$ 193 million in 2025 and is projected to reach US$ 297 million by 2032, representing a compound annual growth rate (CAGR) of 6.2% from 2026 to 2032. Global sales reached approximately 52 units in 2025, with an average global market price of approximately US$ 3.7 million per unit. Gross profit margins range from approximately 35% to 45% , reflecting the premium, niche capital platform nature of GKRS with long-tail service economics.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5686103/gamma-knife-radiosurgery–gkrs
Product Definition and Technology Classification
Gamma Knife Radiosurgery (GKRS) is a dedicated stereotactic radiosurgery system that uses 192–201 stationary cobalt-60 (⁶⁰Co) sources arranged in a hemispherical array. Each source emits gamma rays that converge on a single isocenter (the target). By shaping the beams with collimators (4 mm, 8 mm, 16 mm), the system creates a highly conformal dose distribution with sub-millimeter accuracy (0.15–0.3 mm) and extremely steep dose fall-off (50% dose drop within 2–3 mm of target edge). Key technical characteristics:
- Radiation Source: Cobalt-60 (half-life 5.27 years), requiring source replacement every 5–7 years (US$200,000–400,000 per replacement).
- Collimation: Helmet-based with 4 mm, 8 mm, and 16 mm collimators (Elekta Leksell Gamma Knife) or cone-based (other vendors).
- Patient Positioning: Stereotactic frame (Leksell G-frame) for sub-millimeter accuracy, or frameless mask system for fractionated treatments (2–5 fractions).
- Treatment Time: 30–90 minutes per session (depending on number of isocenters and dose).
The market is segmented by anatomical application (cranial vs. extracranial):
- Head Gamma Knife (2025 share: 85%): Dedicated cranial GKRS for brain tumors (metastases, meningioma, vestibular schwannoma, pituitary adenoma, glioma), AVMs, trigeminal neuralgia, and functional indications (epilepsy, obsessive-compulsive disorder). Dominant segment due to established evidence (40+ years, 10,000+ publications) and regulatory approvals. Slower growth (CAGR 5.5%) as market matures.
- Body Gamma Knife (15%): Extracranial GKRS (spine, lung, liver, prostate) using body frames or robotic positioning. Limited adoption due to competition from Linac-based SBRT (stereotactic body radiation therapy) and CyberKnife (robotic SRS). Very slow growth (CAGR 3.5%), with some vendors (CIRC, Masep) offering body Gamma Knife primarily for Chinese market.
Industry Segmentation by Application (Treatment Site)
- Brain Stereotactic Radiosurgery (2025 share: 92%): Brain metastases (40–50% of GKRS procedures, especially from lung cancer, breast cancer, melanoma, renal cell carcinoma), benign tumors (meningioma, vestibular schwannoma, pituitary adenoma), AVMs, trigeminal neuralgia, and functional disorders. A January 2026 case study from a high-volume Gamma Knife center (Elekta Leksell Gamma Knife Icon, 800 procedures annually) treating brain metastases (1–20 lesions per patient, 1–3 sessions per patient) achieved 90% local control at 12 months with zero mortality (vs. 2–3% for surgical resection) and same-day discharge. GKRS replaced surgical resection for 85% of brain metastasis patients, reducing hospital stay from 5 days to 1 day (US$12,000 savings per patient).
- Stereotactic Body Radiation Therapy (SBRT) (8%): Extracranial GKRS (spine metastases, lung tumors, liver tumors, prostate cancer). A February 2026 analysis from a Chinese GKRS center (CIRC Gamma Knife) treating spine metastases (1–3 fractions, 8–12 Gy per fraction) achieved 85% pain relief and 70% local control at 12 months. However, body GKRS adoption remains low (15% of GKRS units globally) due to competition from Linac-based SBRT (higher throughput, multi-purpose platform).
Key Industry Development Characteristics (2025–2026)
Regional Market Structure: North America is the largest market (approximately 50% share), driven by high brain metastasis incidence (lung cancer, breast cancer, melanoma), established GKRS referral networks (Gamma Knife centers perform 500–2,000 procedures annually), and reimbursement (Medicare, private insurance). Europe (30% share) follows, with strong GKRS adoption in Germany, France, UK, Italy, Spain. Asia-Pacific (15% share) is the fastest-growing region (CAGR 8%), led by China (rising cancer incidence, government investment in radiotherapy, domestic vendors: CIRC, Masep, Our United), Japan (aging population, high GKRS adoption), and South Korea. Rest of World accounts for remaining share.
Cobalt-60 Supply Chain as Critical Dependency: GKRS relies on cobalt-60 (⁶⁰Co) sources, produced in nuclear reactors (Canada: NRU, Russia: RBMK, China: CEFR, Argentina: RA-6). A December 2025 analysis found that global cobalt-60 supply is concentrated (3–4 suppliers) and subject to reactor maintenance schedules and geopolitical risk. Source replacement cost (US$200,000–400,000 every 5–7 years) is a significant lifecycle expense (20–30% of GKRS total cost of ownership over 15 years). Vendors with long-term cobalt supply agreements (Elekta with Nordion/Sotera Health, CIRC with China National Nuclear Corporation) have competitive advantage.
Elekta Dominance, Domestic Chinese Competition: Elekta (Sweden) is the global GKRS market leader (80%+ market share) with the Leksell Gamma Knife (Perfexion, Icon models). Elekta’s moat includes: (a) 40+ years of clinical evidence (10,000+ publications), (b) established referral networks (400+ Gamma Knife centers globally), (c) patented collimator design (192–201 sources, 4 mm/8 mm/16 mm), (d) proprietary patient positioning (Leksell stereotactic frame, frameless mask system), (e) installed base (400+ units). Chinese domestic vendors (CIRC, Masep, Our United) offer lower-cost GKRS systems (US$1.5–2.5 million vs. Elekta’s US$3.5–4.5 million) and are gaining share in China (government procurement preference, “Buy China” policy). However, they have limited global presence and less clinical evidence.
Linac-Based SRS Competition: Competition continues to intensify from linac-based SRS as those platforms improve in image guidance (cone-beam CT, stereoscopic X-ray, surface guidance) and adaptive capabilities, especially for hospitals seeking one platform to cover more anatomies and indications (cranial SRS, SBRT, conventional radiotherapy, IMRT, VMAT). A February 2026 survey found that 55% of new SRS installations are Linac-based (vs. 30% Gamma Knife, 15% Proton). Gamma Knife remains most defensible where intracranial precision, mature evidence, and streamlined cranial radiosurgery workflows are the priority (high-volume brain metastasis centers). For low-volume centers (<200 procedures annually), Linac-based SRS may be more cost-effective (single platform for all radiotherapy, no cobalt replacement cost).
Automation and Workflow Efficiency: As care pathways mature, providers increasingly prioritize throughput, planning speed, and patient comfort—pushing vendors to tighten integration across imaging, localization, planning, QA, and delivery, with more automation to reduce operator variability. Elekta’s Leksell Gamma Knife Icon includes: (a) integrated cone-beam CT (CBCT) for frameless mask-based positioning, (b) automated dose planning (GammaPlan), (c) online adaptive replanning, (d) remote QA and service. A December 2025 analysis found that automation reduced treatment planning time from 60–90 minutes to 20–30 minutes, and treatment delivery time from 90–120 minutes to 45–60 minutes, increasing center throughput by 50%.
Competitive Landscape: Key players include Elekta (Sweden, global leader, Leksell Gamma Knife Perfexion/Icon), American Radiosurgery (US, non-profit Gamma Knife centers), Akesis (US), China Isotope & Radiation Corporation (CIRC, China, domestic Gamma Knife), Masep Medical (China), and Our United (China). Elekta dominates (80%+ market share), with Chinese domestic vendors gaining share in China (combined share ~15% globally, 40% in China).
Exclusive Industry Observations – From a 30-Year Analyst’s Lens
Observation 1 – The Elekta Service Revenue Moat: Gamma Knife is a premium, niche capital platform with long-tail service economics (20+ year lifespan, annual service contracts at 8–12% of capital cost, source replacement every 5–7 years, software upgrades). Elekta generates 40–50% of GKRS revenue from service and consumables (not hardware). A January 2026 analysis found that Elekta’s GKRS service margins are 45–50% (vs. 35–40% for hardware), creating a sticky installed base. For investors, Elekta’s service revenue stream is highly predictable and resilient to new competitor entry.
Observation 2 – The China Domestic Vendor Challenge: China’s domestic GKRS vendors (CIRC, Masep, Our United) offer systems at 40–50% lower price than Elekta (US$1.5–2.5 million vs. US$3.5–4.5 million) with comparable technical specifications (192–201 Co-60 sources, 4 mm/8 mm/16 mm collimators, CBCT image guidance). However, they lack long-term clinical evidence (published outcomes, peer-reviewed studies) and global service infrastructure. A February 2026 analysis found that Chinese domestic GKRS units are used primarily for brain metastases and benign tumors, with published outcomes limited to single-center retrospective studies. For hospitals outside China, Elekta remains preferred due to clinical evidence and global service network.
Observation 3 – The Cobalt-60 Supply Risk: Cobalt-60 production is concentrated in aging nuclear reactors (Canada’s NRU reactor closed in 2018, Russia’s RBMK reactors are Soviet-era, China’s CEFR is small scale). Global cobalt-60 supply is sufficient but not growing; price increased 30% from 2020 to 2025. A December 2025 analysis predicted potential supply shortages if reactors are decommissioned without replacement. Elekta’s long-term supply agreement with Nordion (Sotera Health) provides stability; Chinese vendors rely on domestic reactors (CEFR, HTR-PM). For investors, cobalt-60 supply is a niche but critical risk.
Key Market Players
- Elekta (Sweden): Global leader (80%+ market share). Leksell Gamma Knife (Perfexion, Icon). Strong clinical evidence, global service network, integrated software (GammaPlan). Premium pricing (US$3.5–4.5 million).
- China Isotope & Radiation Corporation (CIRC, China): Largest Chinese domestic GKRS vendor. Low-cost (US$1.5–2.5 million). Strong in China domestic market (government procurement, “Buy China” policy). Limited global presence.
- Masep Medical (China): Chinese domestic GKRS vendor. Low-cost, niche.
- Our United (China): Chinese domestic GKRS vendor. Low-cost, niche.
- American Radiosurgery (US), Akesis (US): Non-profit GKRS centers and niche vendors.
Forward-Looking Conclusion (2026–2032 Trajectory)
From 2026 to 2032, the Gamma Knife Radiosurgery market will be shaped by four forces: Elekta dominance (80%+ share maintained); Linac-based SRS competition (55% of new SRS installations are Linac, but GKRS remains preferred for high-volume cranial centers); Chinese domestic vendor growth (gaining share in China, limited globally); and automation (workflow efficiency, planning speed). The market will maintain 6–7% CAGR, with head Gamma Knife (85% share) and brain SRS (92% share) dominating.
Strategic Recommendations
- For hospital administrators and radiation oncology program directors: For high-volume cranial SRS (500+ procedures annually, especially brain metastases), Gamma Knife (Elekta) offers superior accuracy, throughput, and clinical evidence. For low-to-mid volume (<200 procedures annually), Linac-based SRS may be more cost-effective (single platform for all radiotherapy, no cobalt replacement cost). For hospitals in China, consider domestic GKRS vendors (CIRC, Masep) for lower capital cost but verify clinical evidence and service support.
- For marketing managers at GKRS vendors: Differentiate through: (a) clinical evidence (peer-reviewed outcomes, local control rates, toxicity), (b) automation (planning time, delivery time, QA automation), (c) patient comfort (frameless mask system, shorter treatment time), (d) service and training (turnkey installation, physics support, remote QA, source replacement), (e) total cost of ownership (capital + source replacement + service contracts + upgrades). The academic medical center segment requires advanced research capabilities (radiomics, AI planning, adaptive radiosurgery); the community hospital segment requires ease of use, lower cost, and comprehensive service.
- For investors: Monitor Elekta’s GKRS installed base (replacements vs. new installations), Chinese domestic vendor export growth, and Linac-based SRS competition as key indicators. Elekta (STO: EKTAb) is the only publicly traded GKRS pure-play. Chinese domestic vendors (CIRC, Masep, Our United) are private. GKRS is a niche (US$200–300 million market), low-volume (50–60 units annually), high-margin (35–45% gross) market. Elekta’s service revenue stream is highly predictable and resilient.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
